Therapie einer akuten Strahlenösophagitis mit orodispersiblem Budesonid

Zusammenfassung

Eine Strahlenösophagitis im Rahmen einer therapeutischen Radiotherapie ist weiterhin eine relativ häufige Komplikation. In diesem Fallbericht beschreiben wir eine Patientin, bei der unter einer Therapie mit orodispersiblem Budesonid eine Strahlenösophagitis ohne erkennbare Residuen abheilen konnte.

Abstract

Radiation esophagitis is a common side effect of therapeutic radiotherapy. In this case report, we describe a patient with a complete remission of the esophagitis after therapy with an oro-dispersible budesonide formulation.

Schlüsselwörter

Strahlenösophagitis - Budesonid - Strahlentherapie

Key words

radiation-induced esophagitis - budesonide - radiation therapy

Publikationsverlauf

Eingereicht: 04. Mai 2020

Angenommen: 06. August 2020

Artikel online veröffentlicht:
16. September 2020

• Literatur

• 1 Claßen J, Hoffmann W, Paulsen F. Radiation induced gastrointestinal toxicity-Pathophysiology, Approaches to Treatment and Prophylaxis. Strahlenther Onkol 1998; 174: 82-92
• 2 Mehta V. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Semin Oncol 2004; 31: 42-46
• 3 Belka C, Hoffmann W, Paulsen F. et al. Einsatz von Sucralfat in der Radioonkologie. Strahlenther Onkol 1997; 173: 247-252
• 4 Becker-Schiebe M, Lordick F, Hoffmann W. Treatment of radiation-induced mucocutaneous toxicity. memo – magazine of european medical oncology 2012; 5: 39-42
• 5 Becker-Schiebe M, Mengs U, Schaefer M. et al. Topical Use of a Silymarin-Based Preparation to Prevent Radiodermatitis. Results of a Prospective Study in Breast Cancer Patients. Strahlenther Onkol 2011; 187: 485-491
• 6 Reinshagen M, Hoffmann W, Classen J. et al Randomised, Double-Blind, Placebo-Controlled Phase II Pilot Study on the Efficacy and Tolerability of an Rectal Treatment With Budesonide (2 mg) or Placebo for the Prevention of Acute Radiation Proctitis. Gastroenterology 2012 (Suppl. 1): 182
• 7 Lucendo AJ, Miehlke S, Schlag C. et al. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology 2019; 157: 74-86
• 8 Murro D, Jakate S. Radiation esophagitis. Arch Pathol Lab Med 2015; 139: 827-830
• 9 Grant JD, Shirvani SM, Tang C. et al. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. . Pract Radiat Oncol 2015; 5: e383-e391
• 10 Yazbeck VY, Villaruz L, Haley M. et al. Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J 2013; 19: 231-237
• 11 Zhao H, Jia L, Chen G. et al. A prospective, three-arm, randomized trial of EGCG for preventing radiation-induced esophagitis in lung cancer patients receiving radiotherapy. Radiother Oncol 2019; 137: 186-191
• 12 Koc M, Onuk MD, Koruk M. et al. Therapeutic effect of oral recombinant human granulocyte-macrophage colony-stimulating factor in radiotherapy-induced esophagitis. Hepatogastroenterology 2003; 50: 1297-300